A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%
Launched by TARO PHARMACEUTICALS USA · Aug 18, 2017
Trial Information
Current as of July 16, 2025
Completed
Keywords
ClinConnect Summary
A Multi-Center, Double-Blind, Randomized, Placebo controlled, Parallel-group study, comparing Ivermectin Lotion, 0.5% to Sklice (Ivermectin) Lotion, 0.5% and both active treatment to a placebo control in the treatment of subjects with active infestation with head lice and their Ova
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects 18 years of age or older must have provided IRB-approved written informed consent and sign a HIPAA authorization.
- • Subjects must be willing and able to understand and comply with the requirements of the protocol, including attendance at the required study visits.
- Exclusion Criteria:
- • Subjects with a history of hypersensitivity or allergy to or any component of the study product.
- • Subject with history of irritation or sensitivity to pediculicides or hair care products.
About Taro Pharmaceuticals Usa
Taro Pharmaceuticals USA is a leading specialty pharmaceutical company dedicated to the development, manufacturing, and marketing of high-quality generic and branded prescription medications. With a strong commitment to innovation and patient health, Taro focuses on therapeutic areas such as dermatology, psychiatry, and neurology, aiming to improve patient outcomes through accessible and effective treatment options. The company adheres to stringent regulatory standards and invests in robust clinical research to ensure the safety and efficacy of its products. Taro Pharmaceuticals USA is dedicated to advancing healthcare while fostering strong partnerships within the medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hawthorne, New York, United States
Patients applied
Trial Officials
Catawba Research
Study Chair
http://catawbaresearch.com/contact/
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials